mivenion announces 4 abstracts for fluorescence optical imaging using the Xiralite system (Rheumascan) to be presented at the European League Against Rheumatism (EULAR) 2013 Annual Meeting

Highlights include:
• ICG-enhanced fluorescence optical imaging (FOI) is able to detect typical inflammatory changes in subjects with arthralgia and psoriasis prior to signs of clinically established arthritis. The detection of typical inflammatory changes in subjects with cutaneous manifestations of psoriasis or family history of psoriasis and joint pain but without clinical signs of synovitis or tendinitis suggests that a non-arthritic, subclinical disease stage may precede the onset of clinically active PsA. With the visualization of inflammation in those subjects FOI possibly is a new diagnostic opportunity in incipient PsA. (Abstract #SAT0526)
• In asymptomatic subjects with elevated rheumatoid factor or anti-CCP antibodies, FOI may provide an earliest hint for inflammation. Three clinical cases with elevated IgM-RF or anti-CCP antibodies were reported. None of the subjects had a history of actual or previous inflammatory joint disease, notably no tender or swollen joints or morning stiffness. Clinical examination, CRP and ESR were normal. In contrast, FOI displayed distinct inflammatory changes in the small joints of the hands (wrist, MCP, PIP) in all subjects. (Abstract #AB0754)
• ICG-enhanced fluorescence optical imaging and musculoskeletal ultrasound was used for a comparison in patients with rheumatoid arthritis und osteoarthritis. In both cohorts, FOI and ultrasound showed similar sensitivity both for RA and OA. Therefore, a reliable differentiation of the two diagnoses based on the different imaging phases cannot be made on basis of the performed statistical calculations in this study. (Abstract #AB0713)
• For the first time, an automated, computer-based quantification of fluorescence optical imaging was investigated in patients under treatment. 30 patients with rheumatoid (RA) or psoriatic (PsA) arthritis were examined before starting treatment (visit 1) and at follow-up (visit 2). Treatment response was assessed using DAS28, cFOIAS and the automated calculated DACT. The intra-individual variation reported in this study was 1.1 % + 1.0 (range: 0.04 – 4.9). cFOIAS scores strongly correlate with automated calculated DACT at an average of 0.85. Agreement of declining DAS28 with declining cFOIAS or DACT was found in 53% of the patients. Results imply that even very low changes of the DACT value can be determined. (Abstract #AB0733)

mivenion GmbH is a life-science company focusing on personalized medicine for patients with inflammatory and autoimmune diseases. With its strong expertise in both pharmaceuticals and medical devices, mivenion is providing cutting edge solutions for life-long patient care. A compelling network of academia and industry partners is supporting mivenion in achieving its goals. Broad patent applications are the foundation of mivenion’s proprietary position. mivenion’s drug development candidates comprise both diagnostic and therapeutic properties and are perfectly suited for optimizing each individual treatment case. mivenion’s medical solutions encompass innovative diagnostic imaging and provide evidence on treatment outcome. Xiralite, the leading product of mivenion, enables the Rheumascan procedure. It for the first time provides an integrated solution for patients with inflammatory diseases in the hands. Based on optical technologies, active inflammation is diagnosed at a very early stage with confidence, attractive technical ease, and high patient comfort.

Media contact:
Dr. Michael Schirner
mivenion GmbH
Robert-Koch-Platz 4
10115 Berlin
Germany
Phone +49 30 68837920
info@mivenion.com

This release was published on openPR.